# LIBRETTO-531 (NCT04211337)

> A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04211337
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Loxo Oncology, Inc.
- Conditions: Medullary Thyroid Cancer
- Interventions: Selpercatinib; Cabozantinib; Vandetanib
- Enrollment: 291
- Primary outcome: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)

## Commentary we found

- X threads: 7
- YouTube: 6
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=libretto-531-nct04211337

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04211337", "email": "<work email>"}; the inbox owner confirms by the emailed link.